Abstract-The cardiovascular system shares numerous anatomic and functional pathways with the antinociceptive network. The aim of this study was to investigate whether angiotensin-converting enzyme (ACE) inhibitor treatment could affect hypertension-related hypalgesia. Twenty-five untreated hypertensive patients, together with a control group of 14 normotensive subjects, underwent dental pain perception evaluation by means of a pulpar test (graded increase of test current applied to healthy teeth). After the evaluation of the dental pain threshold (occurrence of pulp sensation) and tolerance (time when the subjects asked for the test to be stopped), all the subjects underwent a 24-hour ambulatory blood pressure monitoring. The hypertensive group then was treated with 20 mg/d enalapril, whereas the normotensive subjects remained without any treatment. After a time interval of 6Ϯ2 months, the dental pain sensitivity was retested in all the subjects, and ambulatory blood pressure was recorded during treatment in the hypertensive patients. At the first assessment, hypertensive patients showed a higher pain threshold than normotensive subjects (PϽ.001). On retesting of pain sensitivity in hypertensive patients, a significant decrease of both pain threshold and tolerance, leading to their normalization, was observed during treatment (PϽ.001 and PϽ.005, respectively), in the presence of reduced 24-hour and office blood pressure values. A slight, though significant, correlation was observed between variations in pain tolerance and baseline blood pressure changes occurring during treatment. During follow-up, the normotensive subjects did not show any significant pain perception or office blood pressure changes. Hypertension-related hypalgesia was confirmed. Mechanisms acting both through lowering of blood pressure and specific pharmacodynamic properties may account for the normalization of pain sensitivity observed in hypertensive patients during treatment with ACE inhibitors. (Hypertension. 1998;31:1146-1150.)
C omplex mechanisms and numerous pathways underlie the pathophysiology of pain perception. 1 The cardiovascular control network shares with the antinociceptive system various central and peripheral neurotransmitters, as well as anatomic nuclei and projections. [1] [2] [3] [4] [5] [6] Experimental studies have also demonstrated a link between the baroreceptor function and pain perception. [7] [8] [9] [10] [11] Modulatory interactions between pain sensitivity and the cardiovascular system have been reported both in physiological conditions and in patients with various cardiovascular syndromes. Alterations in pain sensitivity and circulating ␤-endorphin, an endogenous opioid-like peptide, were found in hypertensive subjects, patients with shock and heart failure, and subjects with silent myocardial ischemia. [12] [13] [14] [15] [16] [17] [18] [19] Both in animal and human studies, hypertension has been associated with a reduced perception of painful stimuli. 12 However, the effect of cardiovascular-acting agents on pain perception has been poorly investigated. Antihypertensive drugs could influence pain sensitivity through blood pressure reduction and/or by specific pharmacodynamic mechanisms. In patients with hypertension, no significant change in pain sensitivity was reported after the use of diuretics or ␤-blockers, whereas ketanserin tended to decrease or reverse the reduced pain perception associated with high blood pressure values. 20, 21 Moreover, interactions between ␤-endorphins, pain sensitivity, and central ␣ 2 -stimulating agents have been reported. [22] [23] [24] [25] [26] The aims of this study were to (1) investigate whether the antihypertensive treatment with enalapril could modify the dental pain threshold and tolerance in human hypertensive subjects and (2) find whether changes in blood pressure levels during treatment could account for possible variations in pain sensitivity.
Methods
Thirty-nine consecutive subjects (mean age, 43Ϯ4 years) with the following characteristics were enrolled in the study: male sex, age between 30 and 50 years, no pharmacological treatment or washout of an antihypertensive therapy for at least 3 weeks, no concomitant diseases (diabetes, neuropathies, cardiac or lung diseases, obesity, stroke, or psychiatric disturbances), dental formula suitable for the pulpar test (see below) as indicated by a previous dental checkup (subjects with tooth fractures, abrasions, caries lesions, fillings, and marked periodontal diseases were excluded), and informed consent to the study. Twenty-five of 39 subjects were hypertensives who were either sent from the general practitioner for blood pressure evaluation or followed up by our center because of a history of hypertension. The 14 healthy normotensive subjects were studied during a general clinical checkup of Italian post office employees and were considered as the control group. A routine diagnostic workup excluded secondary forms of hypertension in all the subjects. Normotensive and hypertensive subjects were similar regarding mean age (44Ϯ5 and 43Ϯ4 years in normotensive and hypertensive subjects, respectively), smoking habits (2 mild smokers in the normotensive group, 4 mild smokers in the hypertensive group), and body mass index (24.6Ϯ1.9 versus 24.7Ϯ1.7 kg/m2 in normotensives and hypertensives, respectively). The study was approved by the ethics committee of our department.
In all subjects, dental pain perception was determined twice (time interval, 6Ϯ2 months) by a pulpar test (performed by the same operator who was blinded to the pressure level of the subjects). The first evaluation (first assessment) was done without any pharmacological treatment. It consisted of a pulpar test preceded by automatic office blood pressure measurements (see "Baseline Blood Pressure") and followed by 24-hour ambulatory monitoring. At the second assessment, the hypertensive patients were receiving angiotensin-converting enzyme (ACE) inhibitor treatment (which was started after the first assessment) while the normotensive subjects remained without any treatment. After a tritiation period, all the hypertensive patients were given enalapril, 20 mg/d, at 7 AM, which was also given the day of the second assessment. In addition to the pulpar test, automatic office blood pressure measurements were repeated at the second assessment in all subjects. Moreover, the hypertensive group underwent additional ambulatory blood pressure monitoring, whereas the normotensive group did not. All subjects were studied at the two assessments after an overnight fast (in particular, the subjects were asked to avoid coffees, teas, cola-containing drinks, alcoholic beverages, chocolate, and smoking during the 12 hours preceding the tests).
Baseline Blood Pressure
In the morning, between 9 and 11 AM, the subjects were kept at rest in a supine and comfortable position for a 30-minute period. Blood pressures were automatically measured by a Hewlett-Packard 78352A recorder every 3 minutes. The blood pressure value of the measurement preceding the pulpar test was defined as baseline blood pressure. If the value differed Ͼ5 mm Hg from the previous measurement, another measure was taken until two were close.
Pain Perception Assessment
After the 30-minute rest, dental pain perception was investigated by means of a pulpar tester. The method has been previously described. 14, 27 Briefly, the pulp stimulator (Medi-tester, Medic-Al) allows the delivery of automatic intermittent bursts of electrical stimuli, with negative polarity at linearly increasing intensity from 0 to 0.03 mA (maximal tension, 6500 mV; burst frequency, 5 Hz). The stimulator was applied to the enamel surface of the tooth through a metal cylinder. The switching on and off occurred automatically when the contact with the tooth was made or excluded, respectively. The hand of the operator in contact with the lips of the subject closed the circuit. As the test current increased from 0 to 0.03 mA, a number from 0 to 80 (relative units [rU] ) was displayed on a digital reader of the instrument (not visible to the subject under examination).
The subjects had been previously instructed to raise their right hand at the occurrence of any pulp sensation (pain threshold, rU). At this point the stimulation was interrupted. Pain tolerance (rU) was obtained by reapplication of the test current immediately afterward and keeping up the stimulation until the subjects asked for the test to be stopped. 14, 27 The pulpar test was performed on three healthy teeth (two upper incisors and one inferior incisor, always in the same order). Mean values (of the three) of pain threshold and tolerance were used in subsequent analysis.
Ambulatory Blood Pressure
After pain perception evaluation, ambulatory blood pressure was recorded by means of a Takeda TM 2421 (A&D Co) set to take a measurement every 15 minutes for a period of 24 hours. In two subjects, the quality of the monitoring was not sufficient (valid measurements Ͻ80%) and was repeated successfully the following day. The reading, editing, and analysis of the data were performed by a software system as previously described. 14, 27 The following parameters were taken into consideration in subsequent analysis: 24-hour systolic and diastolic pressures, 24-hour heart rate, and daytime (7 AM to 10 PM) and nighttime (10 PM to 7 AM) systolic and diastolic pressures.
Statistical Analysis
Data are presented as meanϮSD. The qualitative variable (smoking habit) was compared between normotensive and hypertensive subjects by a 2 test, and possible variations of this variable between the first and second assessment were tested by a McNemar test. Student's t test was used to compare parametric variables between normotensive and hypertensive subjects. A Mann-Whitney U test was performed to compare pain threshold and tolerance between the normotensive and hypertensive groups. Hemodynamic data obtained at the time of the two assessments were compared by a paired t test. A Wilcoxon rank test was used to compare the results of pain perception evaluation at baseline and during follow-up. Possible relations between blood pressure variations and pain sensitivity changes occurring during follow-up were tested by Spearman rank correlation analysis.
The percentage of change of both arterial pressures and pain perception variables between the two assessments were obtained by the following formula: First Assessment ValueϪSecond Assessment Value/First Assessment Valueϫ100 (%). The statistical analysis was performed with the computerized Statistical Package for the Social Sciences (SPSS). A value of PϽ.05 was considered significant.
Results
The 24-hour blood pressure was 141Ϯ11/93Ϯ11 and 123Ϯ12/74Ϯ6 mm Hg in hypertensive and normotensive subjects, respectively (PϽ.001).
The dental pain threshold was significantly higher in the 25 hypertensive patients than in the 14 normotensive subjects (29Ϯ6 versus 22Ϯ4 rU in hypertensives and normotensives, respectively, PϽ.001). The pain tolerance also tended to be higher, although not significantly, in the hypertensive group (48Ϯ18 versus 44Ϯ20 rU, NS).
Follow-up
No difference was found in smoking habits and body mass index between subjects at the first and second assessment.
On retesting of hypertensive patients during chronic treatment with ACE inhibitors, a significant reduction was observed in both 24-hour and baseline blood pressure values (Table) . A significant decrease of pain threshold and tolerance was found when the dental pain sensitivity was retested during pharmacological treatment (PϽ.001 and PϽ.005, respectively) (Fig 1) .
Hemodynamic Variables in Hypertensive Patients
As expected, the control group of normotensive subjects, who remained untreated during follow-up, did not show any significant variation with respect to baseline systolic and diastolic blood pressures or baseline heart rate (first versus second assessment: 136Ϯ13/82Ϯ10 versus 139Ϯ15/ 83Ϯ11 mm Hg, NS; and 64Ϯ13 versus 65Ϯ11 bpm, NS).
Moreover, both pain threshold and tolerance remained unchanged at the second evaluation (Fig 2) .
When pain threshold and tolerance of the normotensive subjects were compared with those of hypertensive patients obtained during treatment with enalapril, no significant difference (previously observed between normotensives and untreated hypertensives) was found. Baseline arterial systolic and diastolic blood pressures were similar in normotensives and enalapriltreated patients. However, although a reduction in 24-hour pressure was observed in the treated hypertensive patients, the ambulatory values remained higher than those recorded in normotensive subjects at the first assessment (PϽ.05 for 24-hour systolic pressure; PϽ.005 for diastolic pressure).
In the hypertensive group, the Spearman rank correlation showed no significant relations between changes (arithmetic difference and percent change) in pain threshold and tolerance and changes in 24-hour blood pressure. However, the baseline systolic and diastolic blood pressure variations were slightly, although significantly, correlated with pain tolerance changes (PϽ.05).
Discussion

Hypalgesia in Hypertension
Hypertension and reduced pain perception have been repeatedly associated in animals and in humans. In humans, various experimental techniques have been used to identify the pain threshold, with similar results. Hypertensive patients show a reduced sensitivity to pain that is independent of the method used to provoke the painful stimuli. 12, 13, 20, [27] [28] [29] [30] The pulpar test may evoke painful pulpal sensations as the test current applied to the tooth under examination gradually increases. Since only A␦ and C fibers are thought to be contained in the pulp, superficial sensations cannot interact with the stimulation of the pain perception pathway. 31, 32 A fair short-term and long-term reproducibility has been reported regarding the pulpar test results in normotensive and hypertensive subjects when they were studied at rest and in a baseline condition. 20, 33, 34 In this study, pain threshold was significantly higher in hypertensive than normotensive subjects, thus confirming a reduced pain sensitivity in patients with high blood pressure levels. The pain tolerance was also higher in hypertensive patients, although the difference did not reach statistical significance. It is a matter of discussion whether hypalgesia is triggered by mechanisms related to increased arterial pressure or it is a feature of hypertension related to the complex alterations of central functions associated with hypertension. 12 However, at least in part, the high pressure values per se seem to have a role in hypalgesia. Hypalgesic behaviors have been associated with various forms of experimental hypertension independently of the method used to induce blood pressure elevation. 35, 36 On reduction of blood pressure, after the removal of the constricted kidney, a normalization of pain threshold was reported in renal hypertensive rats, although occurring with a delayed pattern with respect to blood pressure changes. 37 The lowering of blood pressure in rats by peripherally acting ganglionic blockers reversed hypalgesia in the hypertensive strain and induced hyperalgesia in the control rats.
38
ACE Inhibitors and Pain Perception
Only a few studies have investigated the possible interactions between antihypertensive agents and pain perception in humans. In this study, the treatment with the ACE inhibitor enalapril was associated with a change in both pain threshold and tolerance, with pain sensitivity being higher during treatment. When the dental pain perception and blood pressure values were retested during follow-up, the control group of untreated normotensive subjects showed unchanged results.
Regarding the effect of ACE inhibitors on pain sensitivity, controversial results have been found in animal studies. Both a significant reduction of hypalgesic behavior and no diminished responsiveness to noxious stimuli were reported in hypertensive animals treated with ACE inhibitors. [39] [40] [41] Angiotensin II (Ang II) seems to antagonize morphine-and electroacupuncture-induced analgesia. [42] [43] On the other hand, other authors have reported that intracerebroventricular angiotensin produced a large analgesic effect that could be blocked by naloxone. 44 Moreover, the dermorphin-induced antinociception was markedly reduced by coadministration of captopril in mice. 45 In addition, Ang II was found to induce baroreflex resetting independently of blood pressure levels 46 ; thus this action on baroreceptor function might affect the perception pattern. At a central level, the activity of Ang II has been reported at the nucleus tractus solitarii and area postrema, which are anatomic regions of primary interest both in blood pressure regulation and pain perception. 47, 48 Captopril acts as a kininasi II inhibitor and reduces degradation of bradykinin. This nonapeptide and its related kinins may induce pain, and the facilitation to bradykinin may account for the enhancement of the algesic effect of phenylbenzoquinone and formalin found in animals pretreated with captopril. 49, 50 Thus, the actions of ACE inhibitors may affect pain perception at various levels. We tested only enalapril to avoid potential intraclass differences on pain sensitivity.
In our study, the significant increase in pain sensitivity observed during treatment with enalapril in the group of hypertensive subjects led to a normalization of pain perception. Pain threshold and tolerance in the treated patients decreased to levels similar to those of normotensives, yet in the presence of 24-hour blood pressure values higher than those of normotensives.
However, some limitations of this study have to be acknowledged: the patient population was relatively small, and the investigation was not designed as a placebo-controlled study.
The individual pattern of pain perception seems to be one relevant factor in the determination of symptoms during myocardial ischemia, and a generalized impaired pain sensitivity has been associated with silent ischemia. [15] [16] [17] Moreover, a role of hypertension in the development of silent ischemia has been reported. 51, 52 These results suggest that ACE inhibitors may facilitate the perception of painful stimuli and, at least in hypertensive patients with coronary artery disease, may possibly interfere with silent episodes.
A recent study investigating pain threshold by hot-plate test in normotensive Wistar-Kyoto and spontaneously hypertensive rats (SHR) after ACE inhibitor treatment found a normalization of the increased hot-plate latencies normally exhibited by SHR, whereas pain sensitivity was unaffected by hydralazine, otherwise effective in reducing blood pressure. 41 In the same study, the treatment with losartan, an angiotensin type 1 (AT 1 ) receptor antagonist, had no effect on blood pressure at the dose used, in the presence of markedly reduced hot-plate latencies. 41 Thus, the authors favored the hypothesis of an interplay between renin-angiotensin mechanisms and intrinsic analgesic modulation in explaining the ACE inhibitor-induced changes in pain sensitivity. Studying spinal nociceptive transmission in rats, Randich and Robertson 53 found that it was significantly attenuated in SHR and that captopril treatment affected the response properties of SHR neurons. However, the findings of that study could not clarify whether this action was obtained by the lowering of arterial pressure or by an influence of the drug on facilitatory or inhibitory systems. 53 In the present study, we found a mild, though significant, relationship between the changes in baseline blood pressure values and pain tolerance reduction. Although the 24-hour blood pressure relates to pain sensitivity better than the standard blood pressure, 27 no significant relation was found between variations of sustained blood pressure induced by therapy and changes in pain perception. The normalization of pain sensitivity found after treatment in the hypertensive group could be related, at least in part, to the drug-induced lowering of blood pressure. Alternatively, the central effects of ACE inhibition or facilitation to bradykinin may account for the increased sensitivity to pain observed after treatment. In our opinion, the increased pain sensitivity may express both variations in mechanisms by which blood pressure affects pain perception and the pharmacodynamic effects of the ACE inhibitors.
